{"entity":{"id":"nct07323641","kind":"trial","name":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of osimertinib and telisotuzumab vedotin in lung cancer, run by Jonsson Comprehensive Cancer Center, now recruiting.","summary":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07323641 by Jonsson Comprehensive Cancer Center, with a registry enrolment figure of 60 participants, started 2026-02-19 and due to reach its primary completion in 2027-02-01. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Osimertinib; Survey Administration; Telisotuzumab Vedotin. Conditions listed: Lung Non-Small Cell Carcinoma. Primary outcome: Objective response rate (ORR); Progression free survival (PFS). Lung eligibility wording from the registry: \"* Cytologically or histologically confirmed non small cell lung cancer (NSCLC), which is incurable with an activating and sensitizing EGFR mutation (e\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07323641","url":"https://clinicaltrials.gov/study/NCT07323641"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc","met-altered-nsclc"],"sections":[],"technologies":["adc","kinase-inhibitors"],"targets":[],"drugs":["osimertinib","telisotuzumab-vedotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07323641","phase":"2","setting":"A Phase II Trial of Telisotuzumab Vedotin With Osimertinib for EGFR Mutated NSCLC With c-MET Overexpression That is Progressing on Osimertinib","sponsor":"Jonsson Comprehensive Cancer Center","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07323641/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}